HXN-2022

N/A

Report date: 2026/04/09 20:00:21

Base Information

Drug NameHXN-2022
Drug Alias NameHXN2022HXN-2022
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-Programmed death-ligand 1
TargetsEpidermal growth factor receptor erbB1Programmed death-ligand 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaN/A
Originator CompaniesEarendil Labs
China Registration ClassN/A

Develop Information

Active CompaniesEarendil Labs
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A